Celadon Pharmaceuticals (CEL) Competitors GBX 16.75 -0.75 (-4.29%) As of 02/21/2025 11:24 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines CEL vs. CNSL, FOX, OTT, BCE, CZN, CHT, DVW, BRCI, NPT, and RCIShould you be buying Celadon Pharmaceuticals stock or one of its competitors? The main competitors of Celadon Pharmaceuticals include Cambridge Nutritional Sciences (CNSL), Fox Marble (FOX), Oxford Technology 3 Venture Capital Trust (OTT), Beacon Energy (BCE), Curzon Energy (CZN), 290005 (CHT.L) (CHT), 5008 (DVW.L) (DVW), BlackRock Comms Income Inv Tst (BRCI), NetPlay TV (NPT), and RapidCloud International (RCI). These companies are all part of the "communication" industry. Celadon Pharmaceuticals vs. Cambridge Nutritional Sciences Fox Marble Oxford Technology 3 Venture Capital Trust Beacon Energy Curzon Energy 290005 (CHT.L) 5008 (DVW.L) BlackRock Comms Income Inv Tst NetPlay TV RapidCloud International Celadon Pharmaceuticals (LON:CEL) and Cambridge Nutritional Sciences (LON:CNSL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership. Do insiders & institutionals have more ownership in CEL or CNSL? 10.7% of Celadon Pharmaceuticals shares are held by institutional investors. Comparatively, 10.2% of Cambridge Nutritional Sciences shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by company insiders. Comparatively, 10.9% of Cambridge Nutritional Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer CEL or CNSL? Celadon Pharmaceuticals received 4 more outperform votes than Cambridge Nutritional Sciences when rated by MarketBeat users. CompanyUnderperformOutperformCeladon PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo VotesCambridge Nutritional SciencesN/AN/A Does the media prefer CEL or CNSL? In the previous week, Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled Cambridge Nutritional Sciences'average media sentiment score. Company Overall Sentiment Celadon Pharmaceuticals Neutral Cambridge Nutritional Sciences Neutral Which has higher earnings & valuation, CEL or CNSL? Cambridge Nutritional Sciences has higher revenue and earnings than Celadon Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCeladon Pharmaceuticals£123.38K83.26-£4.97M-£7.98-2.10Cambridge Nutritional Sciences£9.77M0.74-£3.03MN/AN/A Which has more risk & volatility, CEL or CNSL? Celadon Pharmaceuticals has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, Cambridge Nutritional Sciences has a beta of 3.89, meaning that its stock price is 289% more volatile than the S&P 500. Is CEL or CNSL more profitable? Cambridge Nutritional Sciences has a net margin of -3.36% compared to Celadon Pharmaceuticals' net margin of -4,024.62%. Cambridge Nutritional Sciences' return on equity of -3.34% beat Celadon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Celadon Pharmaceuticals-4,024.62% -187.26% -34.40% Cambridge Nutritional Sciences -3.36%-3.34%-2.36% SummaryCambridge Nutritional Sciences beats Celadon Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Celadon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CEL vs. The Competition Export to ExcelMetricCeladon PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£10.27M£2.35B£5.85B£2.63BDividend YieldN/A2.92%4.76%4.98%P/E Ratio-2.104.2716.51163.28Price / Sales83.26733.09450.02312,084.15Price / Cash3.0510.2538.0128.02Price / Book4.417.507.645.14Net Income-£4.97M£20.70B£3.18B£5.73B7 Day Performance11.67%0.03%-1.95%-0.99%1 Month Performance-26.05%0.15%-0.23%-0.81%1 Year Performance-84.77%98.05%16.69%39.26% Celadon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCeladon PharmaceuticalsN/AGBX 16.75-4.3%N/A-85.0%£10.27M£123,381.65-2.102,780Gap UpCNSLCambridge Nutritional SciencesN/AGBX 3.12-10.8%N/A+19.7%£7.43M£9.77M-362.103,200Gap DownFOXFox MarbleN/AN/AN/AN/A£5.63M£722,064.00-135.0010,600OTTOxford Technology 3 Venture Capital TrustN/AN/AN/AN/A£2.13M£-85,000.00-12.59203Gap DownBCEBeacon EnergyN/AGBX 0flatN/A-95.2%£740,000.00N/A-0.3544,600News CoverageHigh Trading VolumeCZNCurzon EnergyN/AN/AN/AN/A£34,000.00N/A-3.4014,700Gap DownCHT290005 (CHT.L)N/AN/AN/AN/A£0.00N/A0.0020,300DVW5008 (DVW.L)N/AN/AN/AN/A£0.00N/A0.00N/AGap UpBRCIBlackRock Comms Income Inv TstN/AN/AN/AN/A£0.00N/A0.00N/AHigh Trading VolumeNPTNetPlay TVN/AN/AN/AN/A£0.00N/A0.00147,000RCIRapidCloud InternationalN/AN/AN/AN/A£0.00N/A0.0023,000 Related Companies and Tools Related Companies Cambridge Nutritional Sciences Competitors Fox Marble Competitors Oxford Technology 3 Venture Capital Trust Competitors Beacon Energy Competitors Curzon Energy Competitors 290005 (CHT.L) Competitors 5008 (DVW.L) Competitors BlackRock Comms Income Inv Tst Competitors NetPlay TV Competitors RapidCloud International Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:CEL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CEL Stock Alerts